Venus Remedies Ltd Falls 7.08%: 2 Key Events Shaping This Week’s Decline

5 January 2026: Weak Start Amid Market Downturn

Venus Remedies began the week on a subdued note, closing at ₹759.65, down ₹22.60 or 2.89% from the previous Friday’s close of ₹782.25. This decline was in line with the broader market sentiment, as the Sensex also slipped 0.18% to 37,730.95. The stock’s volume was moderate at 965 shares, reflecting cautious trading activity. The initial drop set the tone for a week dominated by technical uncertainty and selling pressure.

6 January 2026: Technical Momentum Shifts Amid Mixed Signals

On 6 January, Venus Remedies’ stock price further declined by 1.15% to ₹750.95, continuing the downward trend. Despite this, technical analysis revealed a nuanced shift from a bullish to a mildly bullish momentum. The Moving Average Convergence Divergence (MACD) remained positive on weekly and monthly charts, signalling sustained medium- to long-term strength. However, the Relative Strength Index (RSI) showed bearish readings, indicating potential overbought conditions and short-term selling pressure.

The stock traded within a volatile intraday range, with a high of ₹798.80 and a low of ₹749.00, suggesting investor indecision. While moving averages supported a positive outlook, the divergence between momentum indicators highlighted a consolidation phase. The Sensex declined 0.19% to 37,657.70, marginally underperforming Venus Remedies’ daily loss.

7 January 2026: Continued Decline Amid Lower Volumes

The downward trajectory persisted on 7 January, with the stock closing at ₹740.10, down 1.44%. Volume dropped to 699 shares, a 37.42% decline compared to the five-day average, signalling waning investor participation. The stock traded below its 5-day and 20-day moving averages, indicating short-term weakness, although it remained above longer-term averages, suggesting the broader uptrend was intact.

The Sensex bucked the trend slightly, gaining 0.03% to 37,669.63, highlighting Venus Remedies’ underperformance relative to the benchmark. This day’s price action reflected growing caution among investors amid mixed technical signals and subdued market sentiment.

8 January 2026: Lower Circuit Hit Amid Heavy Selling Pressure

Venus Remedies faced its most severe setback on 8 January, hitting the lower circuit limit of 5% and closing at ₹711.25, down ₹28.85. The stock’s intraday low of ₹707.10 triggered the circuit breaker, reflecting intense selling pressure and panic among market participants. The total traded volume surged to 2,512 shares, with a turnover of approximately ₹2.46 crore, indicating heightened liquidity but predominantly on the sell side.

This sharp decline was notably worse than the Pharmaceuticals & Biotechnology sector’s 0.76% fall and the Sensex’s 1.41% drop to 37,137.33. The stock’s four-day cumulative loss reached 9.3%, underscoring sustained bearish sentiment. Despite the short-term weakness, the stock price remained above its 50-day, 100-day, and 200-day moving averages, suggesting some underlying long-term support.

The downgrade of the Mojo Grade from 'Strong Buy' to 'Buy' on 6 January reflected this cautious stance amid volatility. The lower circuit activation, absent any specific adverse corporate news, likely stemmed from broader sector pressures and profit-booking activities.

9 January 2026: Partial Recovery on Reduced Market Confidence

The week concluded with a modest rebound as Venus Remedies gained 2.19% to close at ₹726.85 on 9 January. Volume remained elevated at 2,433 shares, but the Sensex continued its decline, falling 0.89% to 36,807.62. This partial recovery suggested some bargain hunting or short-term technical buying, yet the overall weekly performance remained negative.

The stock’s resilience above key long-term moving averages may provide a foundation for stabilisation, but the recent volatility and downgrade in analyst sentiment highlight the need for caution. Investors should monitor volume trends and price action closely for signs of sustained recovery or further weakness.

Key Takeaways

Positive Signals: Despite the weekly decline, Venus Remedies remains above its 50-day, 100-day, and 200-day moving averages, indicating that the long-term uptrend is intact. The MACD and KST technical indicators continue to show bullish momentum on weekly and monthly timeframes, suggesting underlying strength beyond short-term volatility.

Cautionary Signals: The stock’s four-day losing streak culminating in a lower circuit hit reflects significant selling pressure and investor panic. The downgrade from 'Strong Buy' to 'Buy' and bearish RSI readings highlight weakening short-term momentum. Reduced delivery volumes and underperformance relative to the sector and Sensex underscore the need for vigilance amid uncertain market conditions.

Conclusion

Venus Remedies Ltd’s performance this week was characterised by a complex interplay of technical momentum shifts and market volatility. The stock’s 7.08% weekly decline outpaced the Sensex’s 2.62% fall, driven by a combination of profit-booking, sector pressures, and cautious investor sentiment. While long-term technical indicators and moving averages provide some reassurance, the short-term weakness and lower circuit event signal a period of consolidation or correction.

Investors should closely monitor upcoming price action and volume trends to gauge whether the stock can stabilise and resume its upward trajectory. The mixed signals warrant a balanced approach, recognising both the stock’s strong historical performance and the current challenges it faces in a volatile market environment.

Unlock special upgrade rates for a limited period. Start Saving Now →